Inhibitory effects of evodiamine on human osteosarcoma cell proliferation and apoptosis

Xiaodong Bai1, Hai Meng1, Lifeng Ma1

  • 1Department of Orthopedics, Beijing Friendship Hospital, Capital Medical University, Xicheng, Beijing 100050, P.R. China.

Oncology Letters
|January 27, 2015
PubMed

Insights

Evodiamine, a compound from traditional Chinese medicine, effectively inhibits osteosarcoma cell proliferation and induces apoptosis. It alters key protein levels, including Bcl-2 and Bax, offering a potential therapeutic strategy for bone cancer.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Osteosarcoma is a primary bone cancer affecting children and adolescents.
  • Evodiamine shows anti-tumor effects in various cancers, but its impact on osteosarcoma is unknown.

Purpose of the Study:

  • To investigate evodiamine's effects on osteosarcoma cell proliferation and apoptosis.
  • To explore the molecular mechanisms underlying evodiamine's action in osteosarcoma.

Main Methods:

  • Cell Counting Kit 8 assay for proliferation.
  • Annexin V/propidium iodide staining for apoptosis.
  • Western blot analysis for protein expression (Bcl-2, Bax, caspase-3, survivin).

Main Results:

  • Evodiamine significantly inhibited human osteosarcoma U2OS cell proliferation.
  • Evodiamine induced significant apoptosis in osteosarcoma cells.
  • Evodiamine modulated apoptosis-related proteins: downregulated Bcl-2, caspase-3, survivin, and upregulated Bax.

Conclusions:

  • Evodiamine demonstrates dose-dependent inhibition of osteosarcoma cell proliferation and induction of apoptosis.
  • The mechanism involves the modulation of Bcl-2, Bax, caspase-3, and survivin protein expression.